Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Research & Development (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Research & Development for 12 consecutive years, with $141085.0 as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 44.75% to $141085.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $481172.0, a 16.11% increase, with the full-year FY2025 number at $438416.0, up 7.6% from a year prior.
  • Research & Development was $141085.0 for Q4 2025 at PharmaCyte Biotech, up from $95157.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $320273.0 in Q2 2021 to a low of $45393.0 in Q1 2023.
  • A 5-year average of $136796.2 and a median of $126733.0 in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 227.96% in 2021, then crashed 71.28% in 2023.
  • PharmaCyte Biotech's Research & Development stood at $135220.0 in 2021, then surged by 31.63% to $177996.0 in 2022, then tumbled by 53.91% to $82033.0 in 2023, then grew by 18.82% to $97470.0 in 2024, then skyrocketed by 44.75% to $141085.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Research & Development are $141085.0 (Q4 2025), $95157.0 (Q3 2025), and $126734.0 (Q2 2025).